Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain

Clinical Microbiology and Infection

Volumn 11, Issue 9, 2005, Pages 759-761

  Rivera, A ^a,b   Rebollo, M ^a   Sanchez F ^a,b   Navarro, F ^a,b   Miro E ^a   Mirelis, B ^a,b   Coll, P ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Epidemiology; gyrA; parC; Quinolones; Resistance; Streptococcus pyogenes

Indexed keywords

ALANINE; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PHENYLALANINE; PROLINE; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; SPARFLOXACIN; TYROSINE; VALINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SPAIN; STREPTOCOCCUS PYOGENES;

STREPTOCOCCUS PYOGENES;

EID: 23844508417     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01216.x     Document Type: Article

References (20)

1. Critchley IA, Sahm DF, Thornsberry C, Blosser-Middleton RS, Jones ME, Karlowsky JA. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis 2002; 42: 129-135.
2. Cantón R, Loza E, Morosini MI, Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 2002; 50(suppl S1): 9-24.
3. Blondeau JM, Laskowski R, Bjarnason J, Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000; 14: 45-50.
4. López H, Vilches V, Scarano S et al. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. Int J Antimicrob Agents 2001; 18: 379-382.
5. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US Medical Centers in 1992 and 1993. Antimicrob Agents Chemother 1994; 38: 2419-2425.
6. Blondeau JM, Church D, Yaschuk Y, Bjarnason J, In vitro activity of several antimicrobial agents against 1003 isolates of Streptococcus pyogenes collected from Western Canada. Int J Antimicrob Agents 1999; 12: 67-70.
7. Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45: 3334-3340.
8. Alonso R, Galimand M, Courvalin P. parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513. Antimicrob Agents Chemother 2002; 46: 3686-3687.
9. Schmitz FJ, Boos M, Mayer S, Kohrer K, Scheuring S, Fluit AC. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones. Antimicrob Agents Chemother 2002; 46: 934-935.
10. Richter SS, Diekema DJ, Heilmann KP et al. Fluoroquinolone resistance in Streptococcus pyogenes. Clin Infect Dis 2003; 36: 380-383.
11. Reinert RR, Lutticken R, Al-Lahham A. High-level fluoroquinolone resistance in a clinical Streptoccoccus pyogenes isolate in Germany. Clin Microbiol Infect 2004; 10: 659-662.
12. Yan SS, Fox ML, Holland SM, Stock F, Gill VJ, Fedorko DP. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 2000; 44: 3196-3198.
13. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996; 40: 2760-2764.
14. Muñoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996; 40: 2252-2257.
15. Pestova E, Beyer R, Cianciotto NP, Noskin GA, Peterson LR. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 2000-2004.
16. Bast DJ, Low DE, Duncan CL et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000; 44: 3049-3054.
17. Guerin F, Varon E, Hoi AB, Gutmann L, Podglajen I. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrob Agents Chemother 2000; 44: 2197-2200.
18. González I, Georgiou M, Alcaide F, Balas D, Linares J, de la Campa AG. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother 1998; 42: 2792-2798.
19. Ruoff KL, Whiley RA, Beighton D. Streptococcus. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of Clinical Microbiology, 8th edn. Washington, DC: ASM Press, 2003; 405-421.
20. Cantón R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003; 52: 944-952.